Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $35.11 USD
Change Today +0.87 / 2.54%
Volume 286.5K
ENTA On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

enanta pharmaceuticals inc (ENTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/29/14 - $52.58
52 Week Low
04/1/15 - $30.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

enanta pharmaceuticals inc (ENTA) Related Bloomberg News

View More Bloomberg News

enanta pharmaceuticals inc (ENTA) Related Businessweek News

No Related Businessweek News Found

enanta pharmaceuticals inc (ENTA) Details

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products focuses on mechanisms gram-positive pathogens, including bacteria resistant and marketed macrolides. It has collaboration agreements with AbbVie Inc., Novartis, and National Institute of Allergy and Infectious Diseases. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

52 Employees
Last Reported Date: 12/11/14
Founded in 1995

enanta pharmaceuticals inc (ENTA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $751.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $440.3K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $514.1K
Compensation as of Fiscal Year 2014.

enanta pharmaceuticals inc (ENTA) Key Developments

Enanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3B RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment

Enanta Pharmaceuticals, Inc. announced new preliminary safety and efficacy data from the first cohort of AbbVie’s ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating the regimen of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) with or without ribavirin (RBV) in treatment-naïve, non-cirrhotic, genotype 1 (GT1) chronic hepatitis C patients with severe renal impairment (stage 4 or 5), including those on hemodialysis. The primary endpoint of the study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR). The first ten patients, or 100%, who have reached post-treatment week four to date (n=10 of 20 enrolled) achieved SVR (n=10/10). The RUBY-I study was presented as a late-breaker at The International Liver Congress™ (ILC) 2015, the 50th annual meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. RUBY-I data showed no virologic failures to date. Preliminary safety analyses reported that patients experienced mainly mild or moderate adverse events when receiving VIEKIRAX + EXVIERA with or without RBV, most commonly (> 20%) anemia, fatigue, diarrhea, nausea, dizziness and headache. To date, eight of 13 GT1a patients had a RBV dose interruption. Paritaprevir, Enanta’s lead protease inhibitor, is one of the three direct-acting antivirals (DAAs) included in AbbVie’s HCV treatment regimens approved in the U.S. for genotype 1 chronic hepatitis C virus as VIKIERA PAK®, in the E.U. as VIEKIRAX® + EXVIERA®, and in Canada as HOLKIRA PAK®. AbbVie is responsible for all development and commercialization activities for regimens that contain paritaprevir. Additional Phase 3b studies from AbbVie presented at ILC 2015 included MALACHITE-I and MALACHITE-II data, and TOPAZ-I and TOPAZ-II study design. The MALACHITE studies evaluate adult patients with GT1 chronic HCV infection without cirrhosis receiving VIEKIRAX + EXVIERA with or without RBV compared to treatment with telaprevir with pegylated-interferon and RBV, which remains the standard of care in many regions of the world. The TOPAZ studies will evaluate the effect of SVRon long-term outcomes five years following treatment with VIEKIRAX + EXVIERA with or without RBV in adults with GT1 chronic HCV infection.

Enanta Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 01:35 PM

Enanta Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 01:35 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Jay R. Luly, Chief Executive Officer, President and Director.

Enanta Pharmaceuticals, Inc. Announces AbbVie Submits New Drug Application to the Japanese Ministry of Health, Labour and Welfare for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. announced that AbbVie has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for AbbVie's investigational, once-daily dosed, all-oral, ribavirin (RBV)-free and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment consisting of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r). The submission is for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. Paritaprevir is Enantaâ s lead protease inhibitor identified within the ongoing Enanta-AbbVie collaboration and is one of the two direct-acting antivirals in the treatment regimen. AbbVie is responsible for all development and commercialization activities for regimens that contain paritaprevir. AbbVie studied a two direct-acting antiviral regimen without RBV in Japan due to patient and viral characteristics specific to the Japanese population, including high prevalence of GT1b. In Japan, approximately 1.5 to 2 million people are living with HCV.1 Genotype 1 is the most common HCV genotype in Japan with 60 to 70% of patients infected and, of those, about 95% are infected with the GT1b sub-type.2 AbbVie has previously announced that they expect regulatory approval in Japan in the second half of 2015. Upon commercialization regulatory approval in Japan, Enanta will be entitled to a $30 million milestone payment from AbbVie. The NDA is supported by the Phase 3 GIFT-I study, which met its primary endpoint achieving a 95% (n=106/112) sustained virologic response rate at 12 weeks post-treatment (SVR12) in the sub-group of previously untreated non-cirrhotic adult genotype 1b (GT1b)-infected Japanese patients who were eligible for therapy with IFN and had a high viral load (¥100,000 IU/mL). Additionally, two patients (0.9%) discontinued treatment due to adverse events. GIFT-I (M13-004) is a Phase 3, multi-center study designed to evaluate the efficacy and safety of 12 weeks of treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in adult Japanese patients (n=363) with chronic genotype 1b hepatitis C virus infection. Patients included those without cirrhosis as well as some patients with compensated cirrhosis, of whom some were new to therapy (treatment-na¯ve) and others had failed previous treatment with interferon with or without ribavirin (treatment-experienced). The study consists of two sub-studies. Sub-study one included patients without cirrhosis randomized to OBV/PTV/r or placebo. Sub-study two included patients with compensated cirrhosis, who received open-label treatment with OBV/PTV/r. Within the primary efficacy patient population, there were no on-treatment virologic failures and 2.8% of patients (n=3/109) experienced relapse. In patients without cirrhosis, the most commonly reported adverse events in the treatment arm were nasopharyngitis (16.7% OBV/PTV/r vs. 13.2% placebo), headache (8.8% OBV/PTV/r vs. 9.4% placebo), and oedema peripheral (5.1% OBV/PTV/r vs. 0% placebo).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENTA:US $35.11 USD +0.87

ENTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENTA.
View Industry Companies

Industry Analysis


Industry Average

Valuation ENTA Industry Range
Price/Earnings 8.4x
Price/Sales 5.3x
Price/Book 3.4x
Price/Cash Flow 8.0x
TEV/Sales 4.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENANTA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at